Ipamorelin Therapy

Ipamorelin binds to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells, triggering the release of stored growth hormone in a pulsatile manner that closely resembles the body's natural rhythm. Its selectivity means it does not substantially activate other hormonal pathways, reducing the likelihood of unwanted hormonal fluctuations. The growth hormone released in response to Ipamorelin subsequently stimulates hepatic IGF-1 production, which supports tissue growth, repair, and metabolic function. The peptide's effects are dose-dependent and self-limiting, meaning the pituitary will not release more GH than it is capable of producing.

Ipamorelin is frequently sought by individuals who are new to peptide therapy and are looking for a well-tolerated entry point into growth hormone optimization. Middle-aged adults experiencing fatigue, increased body fat, and reduced recovery are among the most common patients. It is also popular with individuals who have tried other GH secretagogues and prefer Ipamorelin's cleaner hormonal profile.

Ipamorelin is administered via subcutaneous injection, typically in the lower abdomen. Most protocols call for once- or twice-daily injections, with many practitioners recommending bedtime dosing to complement natural GH release. It is commonly used in cycles of 8 to 12 weeks, often in combination with CJC-1295 for enhanced effect.